Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention

PHASE4RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

December 30, 2025

Conditions

Acute Myocardial InfarctionHeart Failure

Interventions

DRUG

SGLT2 inhibitor

In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.

OTHER

Control

In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.

Trial Locations (1)

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER